Clínic Hospital

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Head of the Cardiology Department at the Hospital Clínic de Barcelona and researcher at the National Centre for Cardiovascular Research (CNIC) and at the August Pi Sunyer Biomedical Research Institute (IDIBAPS)

Psychiatrist and researcher at the Bipolar and Depressive Disorders Unit of the Hospital Clínic de Barcelona

Researcher of the Centre for Biomedical Research in Mental Health Network (CIBERSAM). Head of the Psychiatry and Psychology Department at the Hospital Clínic de Barcelona and lecturer at the University of Barcelona

Professor of Medicine at the University of Barcelona and coordinator of the Central Sensitisation Unit at the Hospital Clínic de Barcelona.

Research Professor at IDIBAPS-Hospital Clínic de Barcelona and Scientific Director of CIBEREHD - Carlos III Health Institute

Head of the HIV-AIDS unit, Hospital Clínic-Barcelona

Head of the Immunology Service

Clinical psychologist at the Psychiatry and Psychology Service of the Hospital Clínic de Barcelona and member of the research group Imaging of mood and anxiety disorders at IDIBAPS

Specialist in Immunology at the Immunology Department of the Hospital Clínic de Barcelona, specialising in immune response to anti-infectious vaccines

Head of the Neurology Department at Hospital Clínic de Barcelona and secretary of the Spanish Society of Neurology's Study Group on Behaviour and Dementia

Contents related to this centre

Five out of ten potential treatments move from animal studies to human studies; four to randomised controlled clinical trials; and one in 20 moves on to approval by regulatory agencies, an analysis estimates. Concordance between positive results in animals and in clinical studies is 86%, according to the study, published in PLoS Biology, which pools the findings of 122 published studies on 54 different human diseases.  

Cell therapy

CAR-T cell therapies may, in some cases, produce tumours secondary to treatment. A few months ago, the US Food and Drug Administration (FDA) said it was assessing this risk. Now, a study conducted at Stanford University Medical Center (USA) has tracked 724 patients who received this type of treatment since 2016. Of these, 14 developed another blood tumour, but only one was a T-cell lymphoma that could be a direct consequence of the therapy. Further analysis ruled out this link. The results are published in the journal NEJM


The Lancet Psychiatry publishes the first meta-analysis of the incidence of antidepressant treatment discontinuation symptoms that includes data from more than 20,000 patients collected from 79 randomised controlled trials and observational studies. The study sought to distinguish between symptoms directly caused by medication discontinuation and other ‘non-specific’ symptoms that may be associated with patient or professional expectations (the nocebo effect). The study concludes that one in six to seven patients will experience one or more symptoms directly caused by stopping medication, and one in 35 are likely to experience severe symptoms.  


The Science group is simultaneously publishing four papers (two in the journal Science, one in Science Immunology and one in Science Translational Medicine) that include advances in a sequential vaccination strategy for an effective HIV vaccine. The methods employed aim to obtain broad-spectrum neutralising antibodies and one of the proposals is already in clinical trials. 


The largest meta-analysis to date that studies the risk of children of people with a mental disorder also suffering from some type of mental disorder during their lifetime has been published, with Spanish participation. According to the study, the risk is more than double that of the rest of the population. To explain the study and resolve any doubts that may arise, the Science Media Centre Spain organised an information session with one of the authors, psychiatrist Joaquim Raduà.


An international team, led by the Hospital Clínic-IDIBAPS in Barcelona together with King's College London (UK) and Dalhousie University (Canada), has published the largest meta-analysis to date studying the risk of children of people with mental disorders developing the same, or another type of disorder. The study included more than three million children of parents with different types of disorders and more than 20 million people as a control population. The results, published in the journal World Psychiatry, indicate that, overall, the former have a 1.5 to 3 times higher risk of developing a disorder in their lifetime. According to the authors, in the case of bipolar, depressive or anxiety disorders, the risk of their offspring suffering from some type of disorder is more than 50%.

Apps and depression

Apps developed to treat depression may be beneficial in the management of severe and moderate cases. This is the conclusion of a review and meta-analysis that included 13 studies with up to 16 different apps. The results are published in the journal JAMA Network Open.


Researchers at Northwestern University in the United States have studied the effect of a temporary decrease in sleep on the mood of mice. According to their results, the animals became more hyperactive and hypersexual for a few hours. In addition, the occasional lack of sleep had an antidepressant effect that lasted for a few days and is explained by an increase in the release of dopamine. The results are published in the journal Neuron.


The Karolinska Institute has awarded the Nobel Prize in Medicine or Physiology to Katalin Karikó and Drew Weissman for their groundbreaking discoveries, which have radically changed our understanding of how mRNA interacts with our immune system, and made it possible to develop vaccines at unprecedented speed during the covid-19 pandemic.

HIV prophylaxis

Pre-exposure prophylaxis (PrEP), which usually consists of taking a daily oral anti-HIV drug, is a highly effective measure to prevent HIV infection. However, it only works well if people strictly follow the protocol, and some people end up not adhering to it. To improve this situation, researchers have tested an implant under the skin of non-human primates that releases the antiretroviral drug islatravir and maintains adequate concentrations for at least 20 months. The results, published in the journal Science Translational Medicine, show complete protection against infection with repeated exposure.